Ab Science SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
AB Science SA to Receive EUR 5.9 Million Subsidy as Leader of Consortium Created for Development of New Alzheimer's Disease Therapy
AB Science SA announced the creation of a partnership in the development of a new targeted therapy in Alzheimer's disease. The consortium will receive EUR 8.6 million from Bpifrance, the French state innovation agency, within the framework of the Industrial Strategic Innovation (ISI) program, and gathers together ABScience, the Brain and Spine Institute (ICM), MIRCen from the Atomic Energy Commission (CEA), the National Institute of Health and Medical Research (INSERM), Imagine Foundation and Skuldtech, a biotechnology company specialized in the discovery of biomarkers and development of diagnostic and testing tools companions. AB Science SA, initiator and leader of this project entitled ROMANE (Role of Mast Cells in Neurology), will receive a total amount of EUR 5.9 million from Bpifrance in the form of grants and repayable advances.
Latest Developments for Ab Science SA
- AB Science SA Passes Futility Analysis in Pivotal Clinical Study in Mastocytosis
- AB Science SA Announces Positive Results of Amyothropic Lateral Sclerosis Efficacy Experiments with Masitinib
- AB Science SA and Skuldtech Announce the Identification of New Predictive Markers for Pancreatic Cancer Survival Associated with Masitinib Treatment
- AB Science SA Announces that European Medicines Agency Accepts Marketing Application for Masitinib in the Treatment of Gleevec resistant Gastro-Intestinal Stromal Tumor
Latest Key Developments in Pharmaceuticals
- Share this
- Digg this